Adverse Events Seen With JAK Inhibitors for Myelofibrosis

Opinion
Video

The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
4 experts in this video
4 experts in this video
Image of a woman with blonde hair wearing a black shirt in front of a blue background
Photo of a man with a beard in front of a blue background
4 experts in this video
4 experts in this video
Related Content